Full Text View
Tabular View
No Study Results Posted
Related Studies
Viennese Prevalence Study of Anderson-Fabry Disease (VIEPAF)
This study is currently recruiting participants.
Verified by Medical University of Vienna, March 2009
First Received: March 27, 2009   No Changes Posted
Sponsors and Collaborators: Medical University of Vienna
Medical University of Graz
Information provided by: Medical University of Vienna
ClinicalTrials.gov Identifier: NCT00871611
  Purpose

The prevalence of Anderson - Fabry disease in patients with left ventricular hypertrophy is unclear. The investigators will examine urine - α - Galactosidase activity and globotriaosylceramide isoforms in these patients.


Condition
Fabry Disease
Left Ventricular Hypertrophy

Genetics Home Reference related topics: Chanarin-Dorfman syndrome cholesteryl ester storage disease Fabry disease Farber lipogranulomatosis L1 syndrome long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency mitochondrial trifunctional protein deficiency primary carnitine deficiency succinic semialdehyde dehydrogenase deficiency
MedlinePlus related topics: Urine and Urination
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Prevalence of Anderson - Fabry Disease in Patients With Left Ventricular Hypertrophy

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Prevalence of Anderson - Fabry disease [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

Urine


Estimated Enrollment: 4000
Study Start Date: January 2009
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Detailed Description:

Anderson - Fabry disease (AFD) is a rare, X - linked hereditary systemic lysosomal storage disorder which usually affects the heart. The reported incidence of AFD is between 1 in 117000 and 1 in 240000 live births. Due to a deficiency of the enzyme α - galactosidase, glycosphingo-lipids, primarily globotriaosylceramide, are stored also in endothelial and myocardial cells, leading to morphologic and functional changes. AFD-cardiomyopathy progresses with age and with the course of the disease, leading to reduced life expectancy. We hypothesize, that AFD could be underdiagnosed in patients with only mild or moderate left ventricular myocardial hypertrophy. Early diagnosis of AFD may be relevant since affected patients might benefit from enzyme replacement therapy at early stage of disease. We will examine 4000 consecutive patients with an echocardiographically measured interventricular septum thickness of ≥ 12mm. Urine samples will be collected and Gb3-isoforms, creatinine and α - Galactosidase activity will be measured.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with left ventricular hypertrophy diagnosed by echocardiography

Criteria

Inclusion Criteria:

  • Patients with myocardial septum wall thickness ≥ 12mm

Exclusion Criteria:

  • Patients < 18 years
  • Patients unable to provide urine sample
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00871611

Contacts
Contact: Gerald Mundigler, MD 0043 1 404000 ext 4614 gerald.mundigler@meduniwien.ac.at

Locations
Austria
Department of Internal Medicine II, Div. Cardiology, Vienna General Hospital Recruiting
Vienna, Austria, 1090
Contact: Gerald Mundigler, MD     0043 1 40400 ext 4614     gerald.mundigler@meduniwien.ac.at    
Sponsors and Collaborators
Medical University of Vienna
Medical University of Graz
Investigators
Principal Investigator: Gerald Mundigler, MD Medical University of Vienna, Dept. Internal Medicine, Cardiology
  More Information

Publications:
Responsible Party: Medical University of Vienna ( Mundigler )
Study ID Numbers: VIE190109
Study First Received: March 27, 2009
Last Updated: March 27, 2009
ClinicalTrials.gov Identifier: NCT00871611     History of Changes
Health Authority: Austria: Federal Ministry for Health Family and Youth

Keywords provided by Medical University of Vienna:
Hereditary
Anderson-Fabry
prevalence
heart
hypertrophy
urine
globotriaosylceramide
isoforms
α - Galactosidase

Study placed in the following topic categories:
Pathological Conditions, Anatomical
Lipid Metabolism, Inborn Errors
Hypertrophy, Left Ventricular
Sphingolipidoses
Heart Diseases
Metabolic Diseases
Lysosomal Storage Diseases
Sphingolipidosis
Central Nervous System Diseases
Brain Diseases
Metabolism, Inborn Errors
Hypertrophy
Genetic Diseases, Inborn
Fabry Disease
Genetic Diseases, X-Linked
Ceramide Trihexosidosis
Brain Diseases, Metabolic, Inborn
Lipidoses
Metabolic Disorder
Cardiomegaly
Lipid Metabolism Disorders
Brain Diseases, Metabolic

Additional relevant MeSH terms:
Pathological Conditions, Anatomical
Lipid Metabolism, Inborn Errors
Hypertrophy, Left Ventricular
Sphingolipidoses
Heart Diseases
Metabolic Diseases
Lysosomal Storage Diseases, Nervous System
Lysosomal Storage Diseases
Nervous System Diseases
Central Nervous System Diseases
Brain Diseases
Metabolism, Inborn Errors
Hypertrophy
Genetic Diseases, Inborn
Fabry Disease
Genetic Diseases, X-Linked
Cardiovascular Diseases
Lipidoses
Brain Diseases, Metabolic, Inborn
Cardiomegaly
Lipid Metabolism Disorders
Brain Diseases, Metabolic

ClinicalTrials.gov processed this record on May 07, 2009